SynthesisFrontiers in immunology2025
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).International urology and nephrology · 2026Article
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Article
- Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer.Pathology oncology research : POR · 2026Review
- The prognostic value of pretreatment inflammatory and nutrition-related indices in patients with cardia cancer.Frontiers in nutrition · 2025Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: The therapeutic landscape of locally advanced or metastatic urothelial carcinoma (mUC) is rapidly evolving, and immune checkpoint inhibitors (ICI) have become an integral part of the standard therapy. However, the majority of patients do not benefit from this treatment. Hence, finding prognostic and predictive biomarkers may improve therapeutic decision-making. The aim of this study was to analyze the prognostic and predictive significance of liquid biomarkers (NLR, CRP, PLR, and LDH) in mUC patients treated with ICI. Methods: We collected articles from PubMed, Cochrane, and Embase databases with primary outcomes of overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). Key findings and limitations: We compiled data from a total of 6,673 ICI-treated patients with locally advanced or mUC from 31 articles. Pooled univariate analysis demonstrated that high pre-treatment NLR is significantly associated with worse OS (HR: 2.19; 95% CI: 1.80-2.68) and PFS (HR: 1.90; 95% CI: 1.57-2.31). Similarly, elevated CRP levels were associated with worse OS (HR: 1.75; 95% CI: 1.37-2.24) and PFS (HR: 1.58; 95% CI: 1.26-1.99). Conclusions and clinical implications: Elevated pre-treatment NLR, CRP, PLR, and LDH are significantly associated with worse OS and PFS in ICI-treated urothelial carcinoma patients, suggesting that they have potential prognostic and predictive value in treatment decisions. Patient summary: In this systematic review and meta-analysis we summarized the existing data on inflammatory laboratory biomarkers and their potential impact on immunotherapy outcomes in urothelial cancers. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022291449.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.